BIO ADVANCE

SECURING AMERICA'S BIOTECH CENTURY

Since the Second World War, American researchers and entrepreneurs have pushed the boundaries of science to save lives, grow our economy, and safeguard our national security. Today, the U.S. bioscience industry comprises more than 156,000 business establishments nationwide. In 2025, it supported roughly 9.7 million American jobs and generated approximately $3.2 trillion in total economic output. Small and mid-sized U.S. biotech companies originate roughly half of new drugs launched worldwide and attract nearly twice as much venture capital as the rest of the world combined.

9.7M
American jobs

156K+
business establishments nationwide

$3.2T
in total economic output

BUT AMERICA'S BIOTECH SECTOR NOW FACES ITS MOST SIGNIFICANT CHALLENGE YET.

China has designated biotechnology as a "pillar industry" and is expending massive state resources to dominate the global landscape. China now launches more than a quarter of clinical trials globally and runs early-stage trials much faster and at lower cost than in the United States. From clinical research and contract services to manufacturing, supply chains, and data, the United States risks losing global prominence in developing and making next-generation medicines.

The country that wins the biotech race will not only shape the future of medicine — it will gain an enduring economic and national security advantage. America has the capacity to maintain its biotech leadership, but only if we act urgently and pursue the right strategy: an all-of-government effort that unites policymakers, industry, and the research community.

READ MORE

The following BIO recommendations would boost innovation, investment, competitiveness, resilience, and security across the U.S. biotech ecosystem.

AN ACTION PLAN FOR THE AMERICAN BIOTECH CENTURY

01 **Establish a White House Office of Biotechnology.**

Create and fund a permanent office to lead a coordinated national biotechnology strategy, strengthen U.S. competitiveness, align policy across agencies, and track progress against strategic competitors.

02 **Accelerate the path to first-in-human clinical studies.**

Modernize regulatory pathways so that early-stage drug development is faster and less costly. Reduce delays by centralizing trial center approval processes and contracting and reducing administrative burdens. Build the infrastructure and capabilities to expand at scale.

03 **Modernize and streamline development at all stages in the United States.**

Enable innovative medicines to reach patients sooner by modernizing how they are developed, evaluated, and approved.

04 **Improve patient access to clinical trials.**

Lower hurdles for patients, clinicians, and health systems across the nation to participate in clinical trials.

05 **Ensure sustained support for academic and government biomedical research.**

Provide abundant, predictable, merit-based federal research funding through NIH, FDA, NSF, BARDA, and ARPA-H. Advance policies that help U.S. institutions attract the world's brightest scientific minds.

06 **Enable and incentivize U.S. contract manufacturing capacity and expertise.**

Support advanced manufacturing, resilient manufacturing supply chains, reshoring incentives, reduced permitting delays, biomanufacturing workforce training, and shared scientific infrastructure and data, especially for smaller and mid-sized biotechs.

07 **Strengthen intellectual property protections and economic incentives that drive access to capital.**

Deliver targeted tax incentives, reduced regulatory burdens, and IP reforms that would enable emerging U.S. biotechs to secure capital and grow in the U.S.

1776

America's founders established a nation built on discovery, enterprise, and the freedom to pursue new ideas.

1976

American scientists and entrepreneurs helped launch the modern biotechnology industry.

2026

The United States faces another pivotal strategic moment.

By acting now to advance these policies, U.S. leaders can support the development of new treatments, create high-paying jobs, strengthen our ability to respond to pandemics and biological threats, and secure another century of American biotech leadership.

Bio